Aurobindo Pharma is pleased to report its Q3 financials:

Q3 Standalone Financials:

Total Income Rs.549.42 Crs. (Rs.511.86 Crs.), the EBITDA Rs.93.58 Crs. (Rs.90.49 Crs.) and Net Profit Rs.55.25 Crs. (Rs.60.12 Crs.).

The sales in Q3 were impacted mainly due to lower off take of SSP products on account of fluctuation in Pen-G prices and continued appreciation of Rupee Vs USD.

The Company has completed the transfer of product Dossiers/IPRs to its European Subsidiary. Consequently there is increased provision for the tax. The benefits of globalization of IPRs will accrue in the coming years.

For the nine months ended 31st December 2007, the Total Income, EBITDA and Net Profit stand at Rs.1711.53 Crs (1395.71), Rs.325.82 Crs (241.34) and Rs.214.70 Crs (150.97) respectively.

To view detailed press release click on the attachment. 

Sourced From: Aurobindo Pharma Limited